Company news
C4 Therapeutics, Inc. (NASDAQ:CCCC) news
Every C4 Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its P...
September 3, 2026
C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 11, 2026
C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best...
June 11, 2026
C4 Therapeutics to Participate in Upcoming Conferences
May 20, 2026
C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 12, 2026
C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrad...
April 9, 2026
C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/R...
March 25, 2026
C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
February 26, 2026
C4 Therapeutics to Participate in Upcoming March Conferences
February 23, 2026
C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dex...
February 23, 2026
C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
February 4, 2026
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 26, 2026
C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy...
January 14, 2026
C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
November 25, 2025
C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
November 6, 2025
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering
October 16, 2025
C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatama...
October 1, 2025
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myelom...
September 20, 2025
C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration
September 4, 2025
C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annu...
September 3, 2025
Akamis Bio Announces the Appointment of Andrew Hirsch to the Company’s Board of Directors
August 12, 2025
C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
August 7, 2025
C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
May 7, 2025
C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
February 27, 2025
C4 Therapeutics to Participate in Upcoming March Investor Conferences
February 24, 2025
C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology
January 14, 2025
C4 Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 8, 2025
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential...
December 8, 2024
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors
November 20, 2024
C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial
November 6, 2024
C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin’s Lymphoma at the Ame...
November 5, 2024
C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
October 31, 2024
C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.
October 15, 2024
C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit
October 9, 2024
C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Ph...
September 13, 2024
C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen
September 10, 2024
C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Cong...
September 8, 2024
C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors
September 3, 2024
C4 Therapeutics to Participate in Upcoming September Investor Conferences
August 29, 2024
C4 Therapeutics Announces European Society for Medical Oncology (ESMO) Changed the Previously Accepted CFT1946 Preliminary Phase 1 Abstra...
August 14, 2024
C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 1, 2024
C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO...
July 16, 2024
C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day
July 8, 2024
C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors
June 10, 2024
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 8, 2024
C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum
April 9, 2024
C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF In...
April 8, 2024
C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for ...
March 5, 2024
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Prot...
March 4, 2024
C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
February 22, 2024